 Human recombinant GM-CSF allogeneic bone-marrow transplantation leukaemia double-blind placebo-controlled trial randomised double-blind trial patients leukaemia human recombinant granulocyte macrophage colony-stimulating factor GM-CSF placebo days allogeneic sibling bone-marrow transplantation neutrophil count days GM-CSF group placebo group significant median neutrophil count days GM-CSF group /l lymphocyte count GM-CSF placebo group days transplantation difference incidence graft-versus-host disease evidence GM-CSF incidence leukaemic relapse GM-CSF group haemoglobin concentrations platelet counts plasma urea creatinine bilirubin placebo group duration hospital stay patient groups Further studies overall effect GM-CSF outcome allogeneic bone-marrow transplantation